Pfizer Inc. (PFE) Return on Invested Capital (ROIC): 8.84%
Is Pfizer Inc.’s return on invested capital (ROIC) high or low?
Pfizer Inc.'s return on invested capital (ROIC) of 8.84% is 15% below its 5-year average of 10.43%, around the middle of its 5-year range (2.80%–21.49%).
As of Wednesday, June 17, 2026. 2.43% below its 12-month average of 9.06%.
PFE Return on Invested Capital (ROIC) Chart
PFE Average Return on Invested Capital (ROIC) Chart
PFE Current vs Average Return on Invested Capital (ROIC) Chart
PFE Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
8.84%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
9.06%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
10.60%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
10.43%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
9.33%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
8.09%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
8.97%
CURRENT VS TTM AVG
-2.43%
CURRENT VS 3Y AVG
-16.62%
CURRENT VS 5Y AVG
-15.27%
CURRENT VS 10Y AVG
-5.28%
CURRENT VS 15Y AVG
+9.28%
CURRENT VS 20Y AVG
-1.44%
PFE Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $148.41B | 8.84% | 9.06% | 10.60% | 10.43% |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 13.71% | 12.85% | 12.25% | 11.92% |
| Abbott Laboratories (ABT)vs › | $157.84B | 8.43% | 9.16% | 9.70% | 9.86% |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 21.53% | 11.95% | 11.58% | 9.92% |
| Danaher Corporation (DHR)vs › | $128.06B | 5.72% | 5.90% | 6.54% | 6.70% |
| CVS Health Corporation (CVS)vs › | $127.73B | 4.72% | 4.17% | 4.46% | 4.93% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 7.58% | 7.80% | 8.16% | 9.10% |
| Stryker Corporation (SYK)vs › | $119.06B | 8.53% | 10.14% | 10.34% | 10.08% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $115.02B | 18.12% | 10.38% | 14.75% | 17.51% |
| Bristol-Myers Squibb Company (BMY)vs › | $114.19B | 13.90% | 13.75% | 11.92% | 10.17% |
Capital Efficiency
ROIC
8.8%
ROE
8.3%
Pfizer Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Pfizer Inc. (PFE)?
- The return on invested capital (ROIC) for PFE stock is 8.84%.
- Is Pfizer Inc.'s return on invested capital (ROIC) high or low?
- Pfizer Inc.'s return on invested capital (ROIC) of 8.84% is 15% below its 5-year average of 10.43%, around the middle of its 5-year range (2.80%–21.49%).
- What is the TTM average return on invested capital (ROIC) for Pfizer Inc. (PFE)?
- The TTM average return on invested capital (ROIC) for PFE stock is 9.06%.
- What is the 3Y average return on invested capital (ROIC) for Pfizer Inc. (PFE)?
- The 3Y average return on invested capital (ROIC) for PFE stock is 10.60%.
- What is the 5Y average return on invested capital (ROIC) for Pfizer Inc. (PFE)?
- The 5Y average return on invested capital (ROIC) for PFE stock is 10.43%.
- What is the 10Y average return on invested capital (ROIC) for Pfizer Inc. (PFE)?
- The 10Y average return on invested capital (ROIC) for PFE stock is 9.33%.
- What is the 15Y average return on invested capital (ROIC) for Pfizer Inc. (PFE)?
- The 15Y average return on invested capital (ROIC) for PFE stock is 8.09%.
- What is the 20Y average return on invested capital (ROIC) for Pfizer Inc. (PFE)?
- The 20Y average return on invested capital (ROIC) for PFE stock is 8.97%.
Pfizer Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 8.84% |
| 2024-12-31 | 9.28% |
| 2023-12-31 | 2.80% |
| 2022-12-31 | 21.49% |
| 2021-12-31 | 13.62% |
| 2020-12-31 | 6.57% |
| 2019-12-31 | 4.86% |
| 2018-12-31 | 10.54% |
| 2017-12-31 | 9.51% |
| 2016-12-31 | 8.17% |
| 2015-12-31 | 6.98% |
| 2014-12-31 | 6.84% |
| 2013-12-31 | 7.92% |
| 2012-12-31 | 8.85% |
| 2011-12-31 | 7.68% |
| 2010-12-31 | 9.12% |
| 2009-12-31 | 7.04% |
| 2008-12-31 | 14.77% |
| 2007-12-31 | 12.48% |
| 2006-12-31 | 13.33% |
| 2005-12-31 | 10.18% |
| 2004-12-31 | 12.75% |
| 2003-12-31 | 5.33% |
| 2002-12-31 | 26.22% |
| 2001-12-31 | 25.98% |
| 2000-12-31 | 21.65% |
| 1999-12-31 | 19.63% |
| 1998-12-31 | 26.04% |
| 1997-12-31 | 19.59% |
| 1996-12-31 | 18.85% |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla